Study directors: Kevin Shapiro, MD PhD, and Elysa Marco, MD
Recruiting: Yes
Study Title: A double-blind, placebo-controlled, phase IIb, multi-center, 12-week prospective study to evaluate the efficacy and safety of gemlapodect in adult and adolescent patients with Tourette’s Syndrome
Condition: Tourette’s Syndrome
Purpose: The purpose of this study is to find out whether gemlapodect, an investigational medication, can reduce tics in individuals with Tourette’s Syndrome.
16-17 years old
Diagnosed (or suspected) Tourette’s Syndrome
Moderate-to-severe motor and vocal tics
Uncontrolled seizure disorders
Unstable medical or psychiatric illness
Conditions such as functional tic-like disorder, Huntington’s chorea, malignant TS, autism, severe anxiety, bipolar disorder, schizophrenia, or Parkinson’s disease
Current CBT, CBiT, or neurostimulation
Current use of medications for tics – contact our study team to discuss
Testing: Comprehensive tic assessments, psychiatric questionnaires, and medical evaluations
Frequency of visits: 12 visits over 4 months, 10 in-clinic and 2 telehealth visits
Costs: No costs will be charged for any of the study procedures
Payment: In return for the time, effort, and travel expenses, participants will be compensated $100 per visit
Location: Cortica Marin and Cortica Glendale
Coordinator: Kelly Olvany – kolvany@corticacare.com – (331) 272-1322
Fill out our Interest Form and we will contact you!